India Drug Makers Learn Lesson, Correct Production Process For U.S. FDA
This article was originally published in PharmAsia News
The spate of U.S. FDA blacklisting of India drug making facilities in the past few years appears to have to a massive cleanup as facilities of firms such as Claris Lifesciences, Dr. Reddy's Laboratories and Sun Pharma join the list of the re-approved.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.